HeartBeam earnings date
Want to see BEAT full AI Analyst Report?
HeartBeam (BEAT) Q3 2026 Earnings Report
BEAT Q3 2026 EPS Results
- Actual EPS
- -$0.05
- Consensus EPS
- -$0.09
- Beat/Miss
- Beat by +$0.04
- One Year Ago EPS
- -$0.15
BEAT Q3 2026 Revenue Results
- Actual Revenue
- $0
- Expected Revenue
- $80.00K
- Beat/Miss
- Missed by -$80.00K
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- After Close
- Conference Call
- Thursday, November 12, 2026
HeartBeam's next earnings date is estimated for March 18, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly focused on progress toward heart attack assessment, with favorable clinical results, FDA Breakthrough Device and TAP designations, a confirmed 510(k) pathway, ahead-of-schedule study enrollment, improving operating efficiency, and approximately $10.1 million of pro forma cash. Important unresolved items remain, including final FDA study parameters, reimbursement and coverage decisions, modest commercialization revenue, preliminary partnerships, investigational AI, ongoing losses and cash usage, and NASDAQ minimum bid compliance. Overall, the number and significance of the stated achievements outweighed the challenges.
Management expects to complete pivotal study design in the fourth quarter of this year, potentially enroll the first patient before year-end or certainly in Q1 of 2027, and likely finish the pivotal trial mid-2027; the trial is expected to be probably in around 300 patient size, with approximately 8 centers, possibly 10 centers, and a conservative enrollment assumption of 10 patients a month. Baseline fourth quarter operating cash outflow is expected to be below $2.5 million, and full-year 2026 net operating cash outflow is expected between $12 million and $12.5 million, with pro forma cash of approximately $10.1 million extending the cash runway further into 2027. The reader service is currently indicating a 30-minute commitment, with a possibility of a 15-minute reaction time commitment, 24/7. Management is fully expecting an extension of another 180 days for NASDAQ compliance, and anticipates presenting HEADSTART-ACS results at the cardiology conference in 2027.
- Breakthrough Device Designation and FDA EngagementHeartBeam received FDA Breakthrough Device Designation and was enrolled in the FDA TAP program. Management said these programs provide prioritized interaction, dedicated FDA advisors, faster communication with the FDA, and access to CMS and payers regarding reimbursement requirements.
- 510(k) Regulatory Pathway ConfirmedThe FDA aligned with HeartBeam on a 510(k) pathway for heart attack assessment rather than a De Novo pathway. Management said this clarifies the regulatory path and is expected to shorten the path toward approval.
- ALIGN-ACS Study Demonstrated Comparable AccuracyThe ALIGN-ACS study enrolled 132 adults at emergency departments in two major cardiology centers and found that patient-recorded HeartBeam 3D ECG was as accurate as standard 12-lead ECG for assessing acute coronary syndrome. HeartBeam specificity was 81.8% versus 71.4% for standard 12-lead ECG, while sensitivity was 60.2% versus 63.0%.
- Strong STEMI and Diagnostic Agreement ResultsFor STEMI heart attacks, HeartBeam sensitivity was 82.9% compared with 83.8% for standard 12-lead ECG. The area under the curve was the same for HeartBeam 3D 3-lead ECG and standard 12-lead ECG. Cardiologists also had higher reader agreement with HeartBeam recordings, with Fleiss' kappa of 0.73 versus 0.54 for standard 12-lead ECG.
- Successful Patient Usability in ALIGN-ACSEvery patient in the ALIGN-ACS study was able to successfully obtain a HeartBeam recording, which management described as an encouraging sign for ease of use.
- HEADSTART-ACS Enrollment Completed Ahead of ScheduleHeartBeam completed enrollment ahead of schedule in the HEADSTART-ACS study, its largest heart attack assessment study to date. The study enrolled 486 patients with chest pain at the National Cardiovascular Center Harapan Kita in Jakarta, Indonesia, and data analysis is underway.
- More Than 600 Patients in Heart Attack Assessment StudiesTogether with ALIGN-ACS, HeartBeam now has clinical experience with more than 600 patients in heart attack assessment. The company anticipates presenting HEADSTART-ACS results at a cardiology conference in 2027.
- U.S. Pivotal Study ProgressHeartBeam expects to complete the pivotal study design in the fourth quarter of 2026 and plans to begin the U.S. pivotal study in the first quarter of 2027, or potentially earlier. Management discussed a likely study size of around 300 patients across approximately 8 to 10 centers, although the size and endpoints had not yet been finalized.
- Expanded Clinical Research PartnershipsHeartBeam joined the EU co-funded EXIT-CVD Research Consortium alongside Philips, Medtronic, GE HealthCare, and other global healthcare organizations. HeartBeam will lead the HEART-CHECK study, one of 22 clinical studies examining high-risk patients.
- Progress Toward ReimbursementHeartBeam is working with a reimbursement consultant and engaging CMS, payers, patients, and provider organizations through the FDA TAP program. The company is evaluating coding, coverage, and payment pathways, including a recent Category III CPT code for algorithm-assisted ECG analysis to identify heart attack.
- AI Heart Attack Assessment ResultsIn early internal analysis of HeartBeam recordings, the heart attack assessment AI identified more heart attacks than physicians reading the same recordings. AI sensitivity was about 12 percentage points higher across all heart attacks and 19 percentage points higher for non-ST elevation heart attacks, with similar specificity.
- Arrhythmia AI Validation and CollaborationHeartBeam completed development of its arrhythmia AI model. Its initial atrial flutter algorithm, developed with University Hospital Basel, showed 97% accuracy compared with an electrophysiology study in 600 recordings using standard 12-lead ECGs. The work was presented at the EHRA 2026 European Conference, published in Europace, and the full manuscript was accepted by the Canadian Journal of Cardiology.
- Broad Platform and Intellectual Property PositionManagement described a cardiac platform opportunity of approximately $40 billion affecting more than 50 million patients, with more than 20 million people considered at risk for heart attack detection applications. HeartBeam has 25 issued patents worldwide and can deploy its technology across the HeartBeam card, patch, and remote unit form factors.
- Lower Operating Cash OutflowNet cash used in operating activities was $2.6 million in Q3 2026, down 23% from Q2 2026 and down 18% from Q3 2025. Management said baseline Q4 2026 operating cash outflow is tracking below $2.5 million, ahead of schedule.
- Operating Expense and Net Loss ReductionTotal operating expenses were $3.5 million, down 32% from Q2 2026 and down 35% from Q3 2025. SG&A was $1.3 million versus $2.0 million in Q3 2025, R&D was $2.1 million versus $3.3 million, and net loss was $3.0 million versus $5.3 million.
- Improved Nine-Month Financial MetricsFor the first nine months of 2026, operating expenses were $13.3 million versus $15.8 million, a 16% decrease. Net loss was $12.7 million versus $15.7 million, and cash used in operating activities was $9.5 million versus $11.1 million, a 14% decrease.
- Improved Cash Position and Lower Full-Year Outflow GuidanceCash and cash equivalents totaled $6.1 million at September 30, 2026, compared with $4.4 million at year-end 2025. HeartBeam subsequently raised approximately $4 million of net proceeds through its at-the-market facility, resulting in pro forma cash of approximately $10.1 million. Full-year 2026 net operating cash outflow is now expected to be between $12 million and $12.5 million, compared with prior guidance of below $14 million.
- NASDAQ Compliance StrategyManagement said it is in communication with NASDAQ and remains in good standing. The company is fully expecting an additional 180-day extension related to the minimum bid compliance deadline and believes it can regain compliance organically.
BEAT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 18, 2027 | 2026 (Q4) | -0.05- | -0.14 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | -0.09-0.05 | -0.15 | 66.67% (+0.10) | |
| Aug 13, 2026 | 2026 (Q2) | -0.09-0.10 | -0.15 | 33.33% (+0.05) | |
| May 13, 2026 | 2026 (Q1) | -0.14-0.12 | -0.18 | 33.33% (+0.06) | |
| Mar 12, 2026 | 2025 (Q4) | -0.14-0.14 | -0.18 | 22.22% (+0.04) | |
| Nov 13, 2025 | 2025 (Q3) | -0.13-0.15 | -0.19 | 21.05% (+0.04) | |
| Aug 13, 2025 | 2025 (Q2) | -0.16-0.15 | -0.19 | 21.05% (+0.04) | |
| May 13, 2025 | 2025 (Q1) | -0.15-0.18 | -0.17 | -5.88% (-0.01) | |
| Mar 13, 2025 | 2024 (Q4) | -0.19-0.18 | 0.07 | -357.14% (-0.25) | |
| Nov 07, 2024 | 2024 (Q3) | -0.17-0.19 | -0.13 | -46.15% (-0.06) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


